Skip to main content
Average ER Wait Time
Checking ER Wait Time
The feed could not be reached
Lafayette Regional Health Center

Cancer Care

Sarah Cannon at Lafayette Regional Health Center is proud to be part of the Sarah Cannon HCA Midwest Health cancer network, providing local access to innovative clinical research trials, tumor profiling and genetic counseling; you can receive top cancer care in the comfort of your community hospital.

Sarah Cannon at Lafayette Regional Health Center offers a comprehensive array of diagnostic services such as minimally-invasive technology for diagnosing and treating breast lesions, as well as a range of cancer care services from screenings, cancer treatment and survivorship. The site is staffed by skilled oncology nurses who provide a wide variety of oncology and infusion services.

Take a risk assessment for breast, cervical, colorectal and prostate cancers. Ask about our cancer screenings, which include breast, colorectal, prostate and skin. Sarah Cannon at Lafayette Regional Health Center also offers additional health education, including tips that may help decrease the risk of developing cancer.

Screenings and Self Assessments

Breast Cancer Colon Cancer

Visit to take more cancer risk assessments or to schedule a cancer screening. Call (660) 259-6884 for more information.

The Lafayette Regional Health Center is in the process of becoming accredited by the American College of Surgeons, Commission on Cancer (CoC). The CoC publishes the Cancer Programs Practice Profile Reports (CP3R) which includes 6 measures for breast cancer.

The (CP³R) measurement helps facilities to:

  • Ensure patients are treated according to recognized standards of care,
  • Promote quality improvement activities, and
  • Accurately compare clinical performance among CoC accredited cancer programs.

We compared our 2014 breast cases receiving hormone therapy to the most current CoC results of 2013:

Accountability Measure Lafayette Regional Health Center Missouri National
Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or stage IB –III hormone receptor positive breast cancer. 100% 94.3% 92.4%

*The accountability measures were agreed upon by the NQF (National Quality Forum) who facilitated an agreement between the CoC (Commission on Cancer), ASCO (American Society for Conical Oncology) & NCCN (National Comprehensive Cancer Network).

Source: Commission on Cancer, National Cancer Database